Pricing Log in Create free account
Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

KYMR Healthcare Biotechnology

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue
+466.4%
EPS
−40.3%
Free cash flow
−186.6%
Total debt
−66.6%

Quarter to September 2026, against a year earlier

131.69 3.57 +2.79%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
4/9
Altman Z
23.22
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Kymera Therapeutics, Inc. (KYMR) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 4 added · 1 removed · 14 modified
P2I1A: no comparison — low extraction confidence 		Share dilution
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 27, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Jun 25, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 24, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 5, 2026 5.02 Departure or appointment of directors or officers
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 25, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits
8-K Feb 26, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 49 added · 36 removed · 52 modified
1A: 20 added · 5 removed · 117 modified
7: 15 added · 4 removed · 26 modified
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 8, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 8, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 8, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 27, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 9, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 27, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Jan 14, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 4, 2024 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.